Special Articles

2012 American College of Rheumatology guidelines for management of gout. Part 2: Therapy and antiinflammatory prophylaxis of acute gouty arthritis

  1. Dinesh Khanna1,†,‡,
  2. Puja P. Khanna1,†,§,
  3. John D. Fitzgerald2,†,
  4. Manjit K. Singh3,
  5. Sangmee Bae2,
  6. Tuhina Neogi4,
  7. Michael H. Pillinger5,¶,
  8. Joan Merill6,
  9. Susan Lee7,
  10. Shraddha Prakash1,
  11. Marian Kaldas2,
  12. Maneesh Gogia2,
  13. Fernando Perez-Ruiz8,‖,
  14. Will Taylor9,
  15. Frédéric Lioté10,††,
  16. Hyon Choi4,‡‡,
  17. Jasvinder A. Singh11,§§,
  18. Nicola Dalbeth12,¶¶,
  19. Sanford Kaplan13,
  20. Vandana Niyyar14,‖‖,
  21. Danielle Jones14,
  22. Steven A. Yarows15,
  23. Blake Roessler1,
  24. Gail Kerr16,†††,
  25. Charles King17,
  26. Gerald Levy18,
  27. Daniel E. Furst2,
  28. N. Lawrence Edwards19,‡‡‡,
  29. Brian Mandell20,§§§,
  30. H. Ralph Schumacher21,¶¶¶,
  31. Mark Robbins22,
  32. Neil Wenger2,
  33. Robert Terkeltaub7,‖‖‖,*

Article first published online: 28 SEP 2012

DOI: 10.1002/acr.21773

Issue

Arthritis Care & Research

Arthritis Care & Research

Volume 64, Issue 10, pages 1447–1461, October 2012

Additional Information

How to Cite

Khanna, D., Khanna, P. P., Fitzgerald, J. D., Singh, M. K., Bae, S., Neogi, T., Pillinger, M. H., Merill, J., Lee, S., Prakash, S., Kaldas, M., Gogia, M., Perez-Ruiz, F., Taylor, W., Lioté, F., Choi, H., Singh, J. A., Dalbeth, N., Kaplan, S., Niyyar, V., Jones, D., Yarows, S. A., Roessler, B., Kerr, G., King, C., Levy, G., Furst, D. E., Edwards, N. L., Mandell, B., Schumacher, H. R., Robbins, M., Wenger, N. and Terkeltaub, R. (2012), 2012 American College of Rheumatology guidelines for management of gout. Part 2: Therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res, 64: 1447–1461. doi: 10.1002/acr.21773

Author Information

  1. 1

    University of Michigan, Ann Arbor

  2. 2

    University of California, Los Angeles

  3. 3

    Rochester General Health System, Rochester, New York

  4. 4

    Boston University Medical Center, Boston, Massachusetts

  5. 5

    VA Medical Center and New York University School of Medicine, New York

  6. 6

    Oklahoma Medical Research Foundation, Oklahoma City

  7. 7

    VA Healthcare System and University of California, San Diego

  8. 8

    Hospital Universitario Cruces, Vizcaya, Spain

  9. 9

    University of Otago, Wellington, New Zealand

  10. 10

    Université Paris Diderot, Sorbonne Paris Cité, and Hôpital Lariboisière, Paris, France

  11. 11

    VA Medical Center and University of Alabama, Birmingham

  12. 12

    University of Auckland, Auckland, New Zealand

  13. 13

    Oral and Maxillofacial Surgery, Beverly Hills, California

  14. 14

    Emory University, Atlanta, Georgia

  15. 15

    IHA University of Michigan Health System, Chelsea

  16. 16

    Veterans Affairs Medical Center, Washington, DC

  17. 17

    North Mississippi Medical Center, Tupelo

  18. 18

    Southern California Permanente Medical Group, Downey

  19. 19

    University of Florida, Gainesville

  20. 20

    Cleveland Clinic, Cleveland, Ohio

  21. 21

    VA Medical Center and University of Pennsylvania, Philadelphia

  22. 22

    Harvard Vanguard Medical Associates/Atrius Health, Somerville, Massachusetts

  1. †

    Drs. Dinesh Khanna, Puja P. Khanna, and FitzGerald contributed equally to this work.

  2. ‡

    Dr. Dinesh Khanna has received consultant fees, speaking fees, and/or honoraria (less than $10,000 each) from Novartis and Ardea and (more than $10,000 each) from Takeda and Savient, and has served as a paid investment consultant for Guidepoint.

  3. §

    Dr. Puja P. Khanna has received speaking fees (less than $10,000) from Novartis and (more than $10,000) from Takeda, and has served on the advisory board for Novartis.

  4. Dr. Pillinger has received speaking fees and/or honoraria (less than $10,000 each) from the RA Investigator Network, NY Downtown Hospital, Winthrop Hospital, and Einstein College of Medicine.

  5. ‖

    Dr. Perez-Ruiz has received consultant fees, speaking fees, and/or honoraria (less than $10,000 each) from Novartis, Menarini, and Savient, and (more than $10,000) from Ardea.

  6. ††

    Dr. Lioté has received consultant fees, speaking fees, and/or honoraria (less than $10,000 each) from Novartis Global, Novartis France, and Ipsen, and has served as a paid investment consultant for Gerson Lehrman Group.

  7. ‡‡

    Dr. Choi has served on the advisory boards (less than $10,000 each) for Takeda, URL, and Savient.

  8. §§

    Dr. Singh has received consultant fees, speaking fees, and/or honoraria (less than $10,000 each) from Ardea, Savient, Allergan, and Novartis, and (more than $10,000) from Takeda, and has received investigator-initiated grants from Takeda and Savient.

  9. ¶¶

    Dr. Dalbeth has received consultant fees, speaking fees, and/or honoraria (less than $10,000 each) from Novartis, Takeda, and Ardea, has received research funding from Fonterra, and holds a patent from Fonterra for milk products for gout.

  10. ‖‖

    Dr. Niyyar has received honoraria (less than $10,000) from the American Society of Nephrology.

  11. †††

    Dr. Kerr has served as a study investigator (more than $10,000 each) for Savient and Nuon.

  12. ‡‡‡

    Dr. Edwards has received consultant fees, speaking fees, and/or honoraria (less than $10,000 each) from Savient, Takeda, Ardea, and Regeneron, and (more than $10,000) from Novartis, and has given expert testimony for Novartis.

  13. §§§

    Dr. Mandell has received consultant fees, speaking fees, and/or honoraria (less than $10,000 each) from Savient, Novartis, and Pfizer.

  14. ¶¶¶

    Dr. Schumacher has received consultant fees (less than $10,000 each) from Pfizer, Regeneron, West-Ward, and Ardea, and (more than $10,000) from Novartis.

  15. ‖‖‖

    Dr. Terkeltaub has received consultant fees (less than $10,000 each) from Takeda, Savient, Ardea, BioCryst, URL, Regeneron, Pfizer, Metabolex, Nuon, Chugai, EnzymeRx, Ajanta, Anadys, Celgene, Isis, and Prescription Solutions, and (more than $10,000) from Novartis, has received grant support from the VA San Diego Healthcare System and the NIH, and has served as a paid investment consultant for Leerink Swann, Medacorp, and Guidepoint.

*VA Healthcare System/University of California, San Diego, 111K, 3350 La Jolla Village Drive, San Diego, CA 92161

  1. †

    Drs. Dinesh Khanna, Puja P. Khanna, and FitzGerald contributed equally to this work.

  2. ‡

    Dr. Dinesh Khanna has received consultant fees, speaking fees, and/or honoraria (less than $10,000 each) from Novartis and Ardea and (more than $10,000 each) from Takeda and Savient, and has served as a paid investment consultant for Guidepoint.

  3. §

    Dr. Puja P. Khanna has received speaking fees (less than $10,000) from Novartis and (more than $10,000) from Takeda, and has served on the advisory board for Novartis.

  4. Dr. Pillinger has received speaking fees and/or honoraria (less than $10,000 each) from the RA Investigator Network, NY Downtown Hospital, Winthrop Hospital, and Einstein College of Medicine.

  5. ‖

    Dr. Perez-Ruiz has received consultant fees, speaking fees, and/or honoraria (less than $10,000 each) from Novartis, Menarini, and Savient, and (more than $10,000) from Ardea.

  6. ††

    Dr. Lioté has received consultant fees, speaking fees, and/or honoraria (less than $10,000 each) from Novartis Global, Novartis France, and Ipsen, and has served as a paid investment consultant for Gerson Lehrman Group.

  7. ‡‡

    Dr. Choi has served on the advisory boards (less than $10,000 each) for Takeda, URL, and Savient.

  8. §§

    Dr. Singh has received consultant fees, speaking fees, and/or honoraria (less than $10,000 each) from Ardea, Savient, Allergan, and Novartis, and (more than $10,000) from Takeda, and has received investigator-initiated grants from Takeda and Savient.

  9. ¶¶

    Dr. Dalbeth has received consultant fees, speaking fees, and/or honoraria (less than $10,000 each) from Novartis, Takeda, and Ardea, has received research funding from Fonterra, and holds a patent from Fonterra for milk products for gout.

  10. ‖‖

    Dr. Niyyar has received honoraria (less than $10,000) from the American Society of Nephrology.

  11. †††

    Dr. Kerr has served as a study investigator (more than $10,000 each) for Savient and Nuon.

  12. ‡‡‡

    Dr. Edwards has received consultant fees, speaking fees, and/or honoraria (less than $10,000 each) from Savient, Takeda, Ardea, and Regeneron, and (more than $10,000) from Novartis, and has given expert testimony for Novartis.

  13. §§§

    Dr. Mandell has received consultant fees, speaking fees, and/or honoraria (less than $10,000 each) from Savient, Novartis, and Pfizer.

  14. ¶¶¶

    Dr. Schumacher has received consultant fees (less than $10,000 each) from Pfizer, Regeneron, West-Ward, and Ardea, and (more than $10,000) from Novartis.

  15. ‖‖‖

    Dr. Terkeltaub has received consultant fees (less than $10,000 each) from Takeda, Savient, Ardea, BioCryst, URL, Regeneron, Pfizer, Metabolex, Nuon, Chugai, EnzymeRx, Ajanta, Anadys, Celgene, Isis, and Prescription Solutions, and (more than $10,000) from Novartis, has received grant support from the VA San Diego Healthcare System and the NIH, and has served as a paid investment consultant for Leerink Swann, Medacorp, and Guidepoint.

Publication History

  1. Issue published online: 28 SEP 2012
  2. Article first published online: 28 SEP 2012
  3. Manuscript Accepted: 15 JUN 2012
  4. Manuscript Received: 9 JAN 2012

Funded by

  • American College of Rheumatology
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH. Grant Number: K24-AR-063120

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS